Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xinkanghe Biomedical Raises $14 Million for Immunology Drugs

publication date: Aug 1, 2023

Suzhou Xinkanghe Biomedical, also known as Kanova Biopharma, raised $14 million in a Series B+ round to advance its pipeline of immunology programs. Founded in 2015, Kanova develops first-in-class therapeutic antibodies or innovative combination therapies to treat cancer and autoimmune diseases. The company’s lead product is XKH004, which targets IL-17A and IL-17F to treat psoriasis and ankylosing spondylitis. The financing was led by Suzhou Gaote Jiaxin Yinhuixin Fund, with participation from Beijing Life Garden Venture Capital, Guangzhou Xintai, Yangzhou Fengsheng, Lotus Lake Ventures, Northern Light Venture Capital and CD Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital